Thiard News@F4F

@newsen.bsky.social

1 week ago

Vanda Pharmaceuticals Urges FDA to Reconsider Slower Drug Review Proposal for FY 2027 Vanda Pharmaceuticals opposes the FDA's FY 2027 proposal that could extend drug review timelines, urging for adherence to the original statutes.

Vanda Pharmaceuticals Urges FDA to Reconsider Slower Drug Review Proposal for FY 2027 #United_States #FDA_Approval #Washington #Vanda_Pharmaceuticals #Drug_Review

Thiard News@F4F

@newsen.bsky.social

1 week ago

Vanda Pharmaceuticals Launches Thetis Study for NEREUS™ to Alleviate Vomiting from GLP-1 Therapies Vanda Pharmaceuticals announces the start of the Thetis trial, aiming to evaluate the efficacy of NEREUS™ in preventing nausea and vomiting linked to GLP-1 therapies in patients.

Vanda Pharmaceuticals Launches Thetis Study for NEREUS™ to Alleviate Vomiting from GLP-1 Therapies #United_States #Washington #Vanda_Pharmaceuticals #GLP-1_therapies #NEREUS™

Thiard News@F4F

@newsen.bsky.social

4 weeks ago

Vanda Pharmaceuticals Urges FDA for Greater Action on Human-Centric Testing Methods Vanda Pharmaceuticals is calling on the FDA to improve regulations around non-animal testing methods in drug development to ensure better patient safety and ethical standards.

Vanda Pharmaceuticals Urges FDA for Greater Action on Human-Centric Testing Methods #United_States #Washington #FDA #Vanda_Pharmaceuticals #animal_testing

Thiard News@F4F

@newsen.bsky.social

1 month ago

Significant Regulatory Milestone: Vanda's HETLIOZ® Hearing on Jet Lag Disorder Approved by the FDA Vanda Pharmaceuticals achieves a groundbreaking approval from the FDA for a hearing on HETLIOZ® concerning jet lag disorder, a significant step in drug regulation.

Significant Regulatory Milestone: Vanda's HETLIOZ® Hearing on Jet Lag Disorder Approved by the FDA #United_States #FDA_Approval #Washington #Vanda_Pharmaceuticals #HETLIOZ®

Thiard News@F4F

@newsen.bsky.social

1 month ago

Vanda Pharmaceuticals to Present at Citizens Life Sciences Conference 2026 in Miami Vanda Pharmaceuticals Inc. will showcase its latest innovations during the 2026 Citizens Life Sciences Conference on March 11 in Miami. Tune in for updates.

Vanda Pharmaceuticals to Present at Citizens Life Sciences Conference 2026 in Miami #USA #Miami #Life_Sciences #Vanda_Pharmaceuticals

Thiard News@F4F

@newsen.bsky.social

1 month ago

Vanda Pharmaceuticals Celebrates FDA Acceptance for Imsidolimab in GPP Treatment Vanda Pharmaceuticals announces that the FDA has accepted its filing for Imsidolimab to treat Generalized Pustular Psoriasis. A potential breakthrough in dermatological therapies.

Vanda Pharmaceuticals Celebrates FDA Acceptance for Imsidolimab in GPP Treatment #USA #Washington #Vanda_Pharmaceuticals #Imsidolimab #Generalized_Pustular_Psoriasis

Thiard News@F4F

@newsen.bsky.social

1 month ago

Vanda Pharmaceuticals Unveils FDA Approval for BYSANTI™, A Breakthrough in Treating Bipolar and Schizophrenia Vanda Pharmaceuticals has received FDA approval for BYSANTI™, a new treatment for Bipolar I Disorder and Schizophrenia, offering hope to millions.

Vanda Pharmaceuticals Unveils FDA Approval for BYSANTI™, A Breakthrough in Treating Bipolar and Schizophrenia #USA #Washington #Vanda_Pharmaceuticals #Bysanti™ #Bipolar_Disorder

Thiard News@F4F

@newsen.bsky.social

2 months ago

Investigation Launched by Pomerantz Law Firm for Vanda Pharmaceuticals Investors' Concerns Pomerantz Law Firm is probing claims on behalf of Vanda Pharmaceuticals investors for potential securities fraud concerns, following FDA news.

Investigation Launched by Pomerantz Law Firm for Vanda Pharmaceuticals Investors' Concerns #United_States #New_York #Pomerantz_Law_Firm #Vanda_Pharmaceuticals #FDA_Decision

Thiard News@F4F

@newsen.bsky.social

2 months ago

Vanda Pharmaceuticals Reports 2025 Financial Growth and Future Prospects for New Treatments Vanda Pharmaceuticals showcases positive financial growth in 2025 and anticipates further advancements in psychiatric medication, particularly with new drug approvals.

Vanda Pharmaceuticals Reports 2025 Financial Growth and Future Prospects for New Treatments #USA #Washington #Nereus #Vanda_Pharmaceuticals #Fanapt

Thiard News@F4F

@newsen.bsky.social

2 months ago

Pomerantz Law Firm Probes Allegations Against Vanda Pharmaceuticals for Securities Fraud Pomerantz LLP is investigating potential securities fraud claims against Vanda Pharmaceuticals Inc. following an FDA setback regarding HETLIOZ.

Pomerantz Law Firm Probes Allegations Against Vanda Pharmaceuticals for Securities Fraud #None #Pomerantz_LLP #Vanda_Pharmaceuticals #Hetlioz

Thiard News@F4F

@newsen.bsky.social

2 months ago

Pomerantz Law Firm Investigates Potential Claims Against Vanda Pharmaceuticals Following FDA Decision Pomerantz LLP is looking into claims by investors of Vanda Pharmaceuticals after the FDA declined to approve its drug for jet lag disorder due to insufficient evidence.

Pomerantz Law Firm Investigates Potential Claims Against Vanda Pharmaceuticals Following FDA Decision #United_States #New_York #Pomerantz_LLP #Vanda_Pharmaceuticals #FDA_Decision

Thiard News@F4F

@newsen.bsky.social

3 months ago

Pomerantz Law Firm Launches Investigation for Vanda Pharmaceuticals Investors Following FDA Setback Pomerantz LLP is conducting an investigation regarding Vanda Pharmaceuticals, as recent FDA developments raise concerns of possible securities fraud.

Pomerantz Law Firm Launches Investigation for Vanda Pharmaceuticals Investors Following FDA Setback #United_States #New_York #Pomerantz_LLP #Vanda_Pharmaceuticals #FDA_Decision

Thiard News@F4F

@newsen.bsky.social

3 months ago

Vanda Pharmaceuticals Faces FDA Setback on HETLIOZ® for Jet Lag Disorder Approval Vanda Pharmaceuticals has received a decision letter from the FDA indicating that the supplemental New Drug Application for HETLIOZ® for jet lag disorder cannot be approved in its current form, citing inadequate evidence of efficacy.

Vanda Pharmaceuticals Faces FDA Setback on HETLIOZ® for Jet Lag Disorder Approval #United_States #Washington #Vanda_Pharmaceuticals #Hetlioz #Jet_Lag_Disorder

Thiard News@F4F

@newsen.bsky.social

3 months ago

Vanda Pharmaceuticals Receives FDA Approval for NEREUS™ to Combat Motion Sickness Vanda Pharmaceuticals' groundbreaking treatment, NEREUS™, has gained FDA approval for motion sickness prevention, marking a significant medical advancement.

Vanda Pharmaceuticals Receives FDA Approval for NEREUS™ to Combat Motion Sickness #United_States #Washington #Vanda_Pharmaceuticals #Tradipitant #NEREUS™

Thiard News@F4F

@newsen.bsky.social

4 months ago

Vanda Pharmaceuticals Submits Biologics License Application for Imsidolimab to Treat Generalized Pustular Psoriasis Vanda Pharmaceuticals has submitted a Biologics License Application for Imsidolimab, a new treatment for Generalized Pustular Psoriasis, to the FDA.

Vanda Pharmaceuticals Submits Biologics License Application for Imsidolimab to Treat Generalized Pustular Psoriasis #United_States #FDA_Approval #Washington #Vanda_Pharmaceuticals #Imsidolimab

Thiard News@F4F

@newsen.bsky.social

4 months ago

FDA Lifts Clinical Restrictions on Tradipitant for Treating Motion Sickness The FDA has removed the partial clinical hold on Tradipitant, allowing Vanda Pharmaceuticals to advance studies for motion sickness treatment, signaling potential breakthroughs.

FDA Lifts Clinical Restrictions on Tradipitant for Treating Motion Sickness #United_States #FDA_Approval #Washington #Vanda_Pharmaceuticals #Tradipitant

Thiard News@F4F

@newsen.bsky.social

4 months ago

Vanda Pharmaceuticals Updates on Tradipitant for Motion Sickness: A Closer Look at Regulatory Progress Vanda Pharmaceuticals has provided significant updates on Tradipitant's regulatory journey, addressing motion sickness with potential FDA approval.

Vanda Pharmaceuticals Updates on Tradipitant for Motion Sickness: A Closer Look at Regulatory Progress #USA #Washington #Vanda_Pharmaceuticals #Tradipitant #Motion_Sickness

Thiard News@F4F

@newsen.bsky.social

5 months ago

Vanda Pharmaceuticals' Tradipitant Shows Promise in Reducing GLP-1 Induced Nausea and Vomiting Vanda Pharmaceuticals has reported positive results from tradipitant, an oral treatment that reduces nausea and vomiting caused by GLP-1 agonists, potentially transforming obesity therapies.

Vanda Pharmaceuticals' Tradipitant Shows Promise in Reducing GLP-1 Induced Nausea and Vomiting #United_States #Washington #GLP-1_Agonists #Vanda_Pharmaceuticals #Tradipitant

Thiard News@F4F

@newsen.bsky.social

5 months ago

October 2025 Health Press Releases: Impactful Updates and Innovations This article highlights the most significant health-related press releases from October 2025. Key updates include new pharmaceutical developments and mental health initiatives.

October 2025 Health Press Releases: Impactful Updates and Innovations #USA #New_York #Novo_Nordisk #Vanda_Pharmaceuticals #Health_Press_Releases

Thiard News@F4F

@newsen.bsky.social

5 months ago

Vanda Pharmaceuticals Reports Impressive Q3 2025 Financial Growth and Future Plans Vanda Pharmaceuticals showcases a remarkable 31% rise in Fanapt sales for Q3 2025, revealing future ambitions including multiple FDA submissions and pipeline advancements.

Vanda Pharmaceuticals Reports Impressive Q3 2025 Financial Growth and Future Plans #United_States #Washington #Vanda_Pharmaceuticals #Fanapt #BIosanti

Thiard News@F4F

@newsen.bsky.social

6 months ago

New York Islanders Form Partnership with Vanda Pharmaceuticals as Jersey Patch Sponsor The New York Islanders announce a historic multi-year agreement with Vanda Pharmaceuticals, marking a significant milestone in NHL's sponsorship landscape.

New York Islanders Form Partnership with Vanda Pharmaceuticals as Jersey Patch Sponsor #USA #New_York #Vanda_Pharmaceuticals #New_York_Islanders #NHL_sponsorship

Thiard News@F4F

@newsen.bsky.social

6 months ago

Monumental Sports Engages Vanda Pharmaceuticals as Founding Partner for New Arena Development Monumental Sports & Entertainment has partnered with Vanda Pharmaceuticals for a new arena in downtown Washington, boosting community engagement.

Monumental Sports Engages Vanda Pharmaceuticals as Founding Partner for New Arena Development #USA #Washington,_D.C. #Vanda_Pharmaceuticals #Monumental_Sports #Capital_One_Arena

Thiard News@F4F

@newsen.bsky.social

6 months ago

Vanda Pharmaceuticals Partners with FDA to Resolve Disputes on Drug Approvals Vanda Pharmaceuticals Inc. has established a collaborative framework with the FDA to settle disputes regarding HETLIOZ and tradipitant. This partnership aims for expedited reviews and clearer pathways for drug approval.

Vanda Pharmaceuticals Partners with FDA to Resolve Disputes on Drug Approvals #United_States #Washington_D.C. #Vanda_Pharmaceuticals #Hetlioz #Tradipitant

Thiard News@F4F

@newsen.bsky.social

6 months ago

Vanda Pharmaceuticals Unveils New Insights on HETLIOZ® for Insomnia Vanda Pharmaceuticals announces findings from a new study showcasing HETLIOZ® effectiveness in improving sleep for patients with primary insomnia.

Vanda Pharmaceuticals Unveils New Insights on HETLIOZ® for Insomnia #USA #Washington #Vanda_Pharmaceuticals #HETLIOZ® #insomnia_study

Thiard News@F4F

@newsen.bsky.social

7 months ago

Vanda Pharmaceuticals Set to Present at Three Major Investor Conferences in September 2025 Vanda Pharmaceuticals will showcase its corporate presentations at key investor conferences in New York and Boston this September, enhancing investor engagement.

Vanda Pharmaceuticals Set to Present at Three Major Investor Conferences in September 2025 #USA #New_York #Investor_Conferences #Vanda_Pharmaceuticals #VNDA

Thiard News@F4F

@newsen.bsky.social

7 months ago

Vanda Pharmaceuticals Secures Orphan Drug Status for Innovative Polycythemia Vera Treatment VGT-1849B Vanda Pharmaceuticals has announced that the FDA has granted Orphan Drug Designation to their new treatment, VGT-1849B, targeting polycythemia vera.

Vanda Pharmaceuticals Secures Orphan Drug Status for Innovative Polycythemia Vera Treatment VGT-1849B #United_States #Washington #Vanda_Pharmaceuticals #Polycythemia_Vera #VGT-1849B

Thiard News@F4F

@newsen.bsky.social

7 months ago

Vanda Pharmaceuticals Urges FDA Review on Generics Approval Decision for Hetlioz® Vanda Pharmaceuticals is seeking an FDA review regarding the approval of generic versions of Hetlioz®, citing serious concerns over the decision-making process.

Vanda Pharmaceuticals Urges FDA Review on Generics Approval Decision for Hetlioz® #USA #Washington #Vanda_Pharmaceuticals #Hetlioz #FDA_Review

Thiard News@F4F

@newsen.bsky.social

7 months ago

Vanda Pharmaceuticals Scores Significant Legal Victory Against FDA for Jet Lag Drug Approval In a landmark decision, Vanda Pharmaceuticals has successfully overturned the FDA's denial of Hetlioz for jet lag treatment, marking a pivotal moment for travelers.

Vanda Pharmaceuticals Scores Significant Legal Victory Against FDA for Jet Lag Drug Approval #United_States #Washington #Vanda_Pharmaceuticals #Hetlioz #Jet_Lag

Thiard News@F4F

@newsen.bsky.social

8 months ago

Vanda Pharmaceuticals Posts Strong Growth in Q2 2025 Financial Results Amid New Drug Approvals Vanda Pharmaceuticals Inc. announces significant financial growth for Q2 2025, highlighted by increased product sales. The company also anticipates critical FDA reviews.

Vanda Pharmaceuticals Posts Strong Growth in Q2 2025 Financial Results Amid New Drug Approvals #USA #Washington #Vanda_Pharmaceuticals #Fanapt #Bysanti

Thiard News@F4F

@newsen.bsky.social

10 months ago

Vanda Pharmaceuticals to Present Key Findings at ASCP Annual Meeting 2025 Vanda Pharmaceuticals is set to participate in the ASCP Annual Meeting 2025, showcasing their innovative findings on new psychiatric therapeutics.

Vanda Pharmaceuticals to Present Key Findings at ASCP Annual Meeting 2025 #United_States #Scottsdale #Vanda_Pharmaceuticals #Bysanti #ASCP_Annual_Meeting